Home » Stocks » SRRA

Sierra Oncology, Inc. (SRRA)

Stock Price: $16.06 USD 0.11 (0.69%)
Updated Jan 15, 2021 4:00 PM EST - Market closed
Market Cap 176.54M
Revenue (ttm) 100,000
Net Income (ttm) -110.34M
Shares Out 10.44M
EPS (ttm) -11.91
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 15
Last Price $16.06
Previous Close $15.95
Change ($) 0.11
Change (%) 0.69%
Day's Open 16.00
Day's Range 15.66 - 16.17
Day's Volume 12,342
52-Week Range 8.88 - 16.70


Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
GlobeNewsWire - 5 months ago

- Ms. Thomson brings extensive strategic, transactional and intellectual property experience as Sierra prepares for potential transition into a commercial company -

Zacks Investment Research - 6 months ago

Sierra Oncology, Inc (SRRA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Seeking Alpha - 10 months ago

Sierra Oncology, Inc. (SRRA) Nick Glover on Q4 2019 Results - Earnings Call Transcript

Zacks Investment Research - 10 months ago

Sierra Oncology (SRRA) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings.

Zacks Investment Research - 11 months ago

Sierra Oncology has been struggling lately, but the selling pressure may be coming to an end soon.

About SRRA

Sierra Oncology researches, develops, and commercializes therapies for the treatment of patients with hematology and oncology needs. Its lead drug candidate, momelotinib, is a selective and orally-bioavailable JAK1, JAK2, and ACVR1 inhibitor that has been investigated in two completed Phase 3 trials for the treatment of myelofibrosis. The company is also advancing SRA737, an orally bioavailable small molecule inhibitor Checkpoint kinase 1 is being investigated in two Phase 1/2 clinical trials; and SRA141, an orally bioavailable small molecule i... [Read more...]

IPO Date
Jul 16, 2015
Stephen Dilly
Stock Exchange
Ticker Symbol
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 4 analysts, the average rating for SRRA stock is "Strong Buy." The 12-month stock price forecast is 27.75, which is an increase of 72.79% from the latest price.

Price Target
(72.79% upside)
Analyst Consensus: Strong Buy